Uproleselan did not significantly improve overall survival in the intent-to-treat population of relapsed/refractory AML patients. Primary refractory AML patients showed a substantial survival benefit ...

Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line ...

Slow, deliberate movement preserves energy and warmth. The post Why Moving Too Fast Is a Major Cause of Survival Failure: ...

Please provide your email address to receive an email when new articles are posted on . Patients who received the neoadjuvant regimen had similar median OS as those who received upfront surgery and ...

New research across seven global biobanks shows that the DNA driving disease onset does not determine survival; instead, lifespan-linked genes and cross-trait scores hold the real clues to prognosis.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced ...